Banglore-based Strides Arcolab and Gilead Sciences have signed a licensing agreement under which Gilead has extended non-exclusive rights to Strides to make and distribute Tenofovir Alafenamide (TAF), both as a single agent product and in combination with other drugs.
TAF is a novel nucleotide reverse transcriptase inhibitor used in human immunodeficiency virus (HIV) patients in the treatment of acquired immunodeficiency syndrome (AIDS).
AIDS / HIV - Treatment
Encyclopedia section of medindia explains in brief about the treatment for AIDS/HIV
Advertisement
TAF is awaiting U.S. Food and Drug Administration (FDA) approval, and is expected to go to market by year-end.
Strides will receive a technology transfer from Gilead, enabling it to make low-cost versions of TAF for developing countries.
A statement from Strides said the licence extends to 112 countries, which together account for more than 30 million people living with HIV.
![AIDS/HIV - Clinical Features]( "AIDS/HIV - Clinical Features")
Encyclopedia section of medindia gives general info about HIV Clinical Features
Strides will be able to launch its product by mid-2016. TAF has demonstrated high antiviral efficacy at a dose 10 times lower than Gilead's Viread (tenofovir disoproxil fumarate), as well as an improved renal and bone safety profile, the statement said.
In September, 2014, Gilead signed agreements with seven Indian generic drug manufacturers licensing them to make sofosbuvir to supply it to 90 countries. Sofosbuvir is priced at $84,000 per patient in the U.S., and the effective price for generic version is around $900 and a 10 percent royalty.
D.G. Shah, Secretary-General, Indian Pharmaceutical Alliance said, "Gilead's chosen voluntary licensing model is refreshing, and will certainly earn it goodwill. It ensures protection of intellectual property and simultaneously ensures access to medicines. Today, its TAF licensing announcement is just an extension of its existing model for developing markets."
"Pharmaceutical multinational prefer Indian manufacturers over other generic manufacturing destinations like South Africa and Brazil because India is already supplying generics to 200 countries and has proven capability, cost-effectiveness and quality," Mr. Shah said.
Source: Medindia
A statement from Strides said the licence extends to 112 countries, which together account for more than 30 million people living with HIV.
AIDS/HIV - Clinical Features
Encyclopedia section of medindia gives general info about HIV Clinical Features
Advertisement
Strides will be able to launch its product by mid-2016. TAF has demonstrated high antiviral efficacy at a dose 10 times lower than Gilead's Viread (tenofovir disoproxil fumarate), as well as an improved renal and bone safety profile, the statement said.
In September, 2014, Gilead signed agreements with seven Indian generic drug manufacturers licensing them to make sofosbuvir to supply it to 90 countries. Sofosbuvir is priced at $84,000 per patient in the U.S., and the effective price for generic version is around $900 and a 10 percent royalty.
D.G. Shah, Secretary-General, Indian Pharmaceutical Alliance said, "Gilead's chosen voluntary licensing model is refreshing, and will certainly earn it goodwill. It ensures protection of intellectual property and simultaneously ensures access to medicines. Today, its TAF licensing announcement is just an extension of its existing model for developing markets."
"Pharmaceutical multinational prefer Indian manufacturers over other generic manufacturing destinations like South Africa and Brazil because India is already supplying generics to 200 countries and has proven capability, cost-effectiveness and quality," Mr. Shah said.
Source: Medindia
It's Not the End of the Road for HIV Patients
HIV patients can lead a normal life if they maintain a positive attitude.
Advertisement
 AIDS/HIV - Prevention And TransmissionEncyclopedia section of medindia explains in brief about the prevention for AIDS/HIV | Advertisement
|
Advertisement
Recommended Reading
Latest AIDS/HIV News
A new study has found that the co-localization of tuberculosis disease and HIV in lymphatic tissues leads to the emergence of potent HIV antibodies.
Specific antiviral drug that is widely used to treat smallpox patients since last summer's outbreak is found to produce similar outcomes regardless of the patient's HIV status.
In susceptible communities because of poverty, and racism, the effects of inadequate STI and HIV screening may be more profound.
In India, annual HIV infections and AIDS-related deaths continue to drop. Between 2010 and 2021, new HIV infections dropped by 46%.
Globally, all countries have promised to end AIDS by 2030, for which it is essential to safeguard individuals living with HIV to complete HIV care services.